亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Peripherally-Acting Cannabinoid Receptor Agonists for Chronic Pain

技術優勢
No centrally-mediated side effectsHigh affinity for cannabinoid receptors
技術應用
Control chronic pain of inflammatory and neuropathic originReduce intraocular pressure
詳細技術說明
Dr. Igor Spigelman of UCLA’s School of Dentistry and Dr. Herbert Seltzman, a collaborator at RTI International, have designed small molecules effective in alleviating chronic pain of inflammatory and neuropathic origin without any centrally-mediated side effects. The molecules are peripherally-acting cannabinoid compounds with high affinity for cannabinoid receptors and have been specifically designed to have limited permeability at the blood-brain barrier.
*Abstract

Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability.  The compounds represent promising therapeutics for treating chronic pain.   
*IP Issue Date
May 23, 2017
*Principal Investigation

Name: Herbert Seltzman

Department:


Name: Craig Shiner

Department:


Name: Igor Spigelman

Department:

申請號碼
9656981
其他

State Of Development

  • Compounds with high agonist activity for CB1R and low BBB permeability were examined for stability in blood plasma
  • Pharmacokinetic studies support minimal brain penetration
  • Preclinical trials in rat models of chronic inflammatory and neuropathic pain have been completed and lead compounds have been identified

Background

Current treatments of different types of chronic pain are geared towards decreasing inflammation (if it exists) and maximizing pain relief while minimizing side effects associated with each particular drug type. Unfortunately, this has been a difficult goal to achieve and all of the current treatments for chronic pain, particularly pain of neuropathic origin, have significant side effects which limit their usefulness. Recently, drugs targeting cannabinoid receptors have proven efficacious for patients. However, while current clinical treatments with FDA-approved cannabinoid-based analgesic can provide relief from chronic pain symptoms, these treatments also produce several significant central nervous system-mediated side effects. 


Tech ID/UC Case

23480/2012-715-0


Related Cases

2012-715-0
國家/地區
美國

欲了解更多信息，請點擊 這裡
移動設備